Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 20Pancreatic Neoplasms 11Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Rectal Neoplasms 5Colonic Neoplasms 5Thyroid Neoplasms 4Multiple Myeloma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Neoplasm Metastasis 3Melanoma 3Hematologic Neoplasms 3Glioma 3Breast Neoplasms 3Bile Duct Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Stomach Neoplasms 1

Interventions

pembrolizumab 3spartalizumab 2trametinib 1tislelizumab 1palbociclib 1nazartinib 1milademetan 1enzalutamide 1devimistat 1dehydroftorafur 1canakinumab 1binimetinib 1bemarituzumab 1aldesleukin 1Specimen Handling 1Pentostatin 1Midazolam 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Interleukin-2 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Early Intervention, Educational 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × trametinib × Gastrointestinal × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔